Tags: New

NCT07231627 – A Prospective Randomized Phase I/II Study of Artificial Intelligence Algorithm-Informed Biopsy for Detection of Prostate Cancer in Patients with Indeterminate and Low-risk prostate MRI lesions

NCT06907043 – A Phase 1/2, Open-Label, Multicenter, Dose-Escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants with Advanced Solid Tumors

NCT07470853 – A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants with Advanced Solid Tumors

NCT07444814 – A Phase 1 First-in-Human Study of PTK7-Directed Antibody-Drug Conjugate HWK-007 in Participants with Advanced Solid Tumors

NCT05554393 – A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy

NCT07061977 – A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

NCT07539155 – Phase Ib/II Study of Intratumoral MMR vaccine injection in borderline resectable/unresectable pancreatic cancer

NCT04637763 – A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Validation of OvaPrintTM cell-free DNA Methylation Liquid Biopsy in women with Pelvic Masses

NCT05561387 – S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance

1
2
3
…
5
Next